Click to open contact form.
Your Global Partners in the Business of Innovation

Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics

Client Update / Feb 25, 2021

Pearl Cohen advises Biolojic Design on intellectual property matters for the Research Collaboration and License Option Agreement with Nektar Therapeutics to develop computationally designed antibodies against a novel target for the potential treatment of autoimmune disease.

Mark Cohen, Senior Partner and Chair of the Life Sciences Practice Group represents Biolojic Design, Ltd. in its intellectual property and patent prosecution matters.

http://www.globenewswire.com/news-release/2021/02/25/2182286/0/en/Biolojic-Design-Enters-a-Research-Collaboration-and-License-Option-Agreement-with-Nektar-Therapeutics-to-Develop-Computationally-Designed-Antibodies-Against-a-Novel-Target-for-the-.html

 

INNOVATION HIGHLIGHTS